A Trail on effectiveness of Platelet Rich Plasma in the management of Oral Lichen Planus compared to steroids

Efficacy of intralesional injection of autologous Platelet Rich Plasma (PRP) in comparison to topical steroids in management of oral lichen planus-A randomized control trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076219

Enrollment

Registered

2024-11-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K137- Other and unspecified lesions of oral mucosa Health Condition 2: L439- Lichen planus, unspecified

Interventions

Intervention1: intralesional platelet rich plasma injection: autologous intralesional injection platelet rich plasma in oral lichen planus for 2 months Control Intervention1: topical corticosteroids:

Eligibility

Inclusion criteria

Inclusion criteria: Clinically and histopathologically confirmed Oral Lichen Planus patients according to classification system proposed by American Academy of Oral and Maxillofacial Pathology in the year 2016. The age group is 18 -88 years

Exclusion criteria

Exclusion criteria: Patients having history of anticoagulant therapy or non-steroidal anti-inflammatory drugs in the past 5 days Patients with h/o HIV infection,Cancer chemotherapy,radiotherapy, Pregnancy. Patients on immune suppressant medication for any other condition.

Design outcomes

Primary

Measure	Time frame
Reduction in Objective and Subjective symptoms of Oral Lichen Planus measured by VAS score and REU scoreTimepoint: 2 months	—

Secondary

Measure	Time frame
Efficacy of Platelet Rich Plasma in Oral Lichen PlanusTimepoint: 2 months	—

Countries

India

Contacts

Public ContactDr Syama P

Kannur Dental College

syamaputhussery96@gmail.com8943095275

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026